Capdevila, Jaume <br/><br/>
What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?  [electronic resource] 

 -  Critical reviews in oncology/hematology  Nov 2014 
 - 83-106 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1879-0461 
<br/><br/><label>Standard No.: </label>10.1016/j.critrevonc.2014.05.004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--therapeutic use<br/>Colorectal Neoplasms--drug therapy<br/>Humans<br/>Indoles--therapeutic use<br/>Receptors, Fibroblast Growth Factor--antagonists & inhibitors<br/>Receptors, Platelet-Derived Growth Factor--antagonists & inhibitors<br/>Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors<br/>Signal Transduction--drug effects